GRIFOLS, S.A.

GRIFOLS, S.A. is a global healthcare company that develops, produces and supplies plasma-derived medicines, biopharmaceuticals, transfusion medicine solutions and clinical diagnostics. Founded in Barcelona in 1909, it treats patients with chronic, rare and life-threatening conditions and provides biological supplies for life-science research and pharmaceutical manufacturing. Its areas of work span immunology, infectious diseases, pulmonology, critical care, hepatology, hematology and neurology.

The company employs more than 23,000 people and operates in more than 30 countries and regions, serving customers in over 110 countries across North America, Europe, Africa, the Middle East and China. It runs the largest network of plasma donation centers globally. Its workforce is multinational and multicultural.

Grifols' product lines include plasma-derived medicines and other biopharmaceutical solutions; a transfusion medicine portfolio designed to enhance safety from donation to transfusion; clinical diagnostic technologies; and biological supplies for research and manufacturing. The company describes itself as a pioneer in the plasma industry and a recognized leader in transfusion medicine, with a stated commitment to improving the health and well-being of people worldwide.